A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults is a research paper published in The Journal of Infectious Diseases (2024). On theSindex it has a DataRank of 0.707. It has been cited 11 times, with 11 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.373
From this paper's citation signal
Citation Network Contribution
0.334
From 9 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 11 citers.
National Institutes of Health
Grant: HHSN272201300018I
NIAID NIH HHS
Grant: HHSN272201300018C
Children’s Healthcare of Atlanta
Georgia Research Alliance
National Institute of Allergy and Infectious Diseases
Emory University School of Medicine
Children's Healthcare of Atlanta
FWCI
2.94
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals